Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms2023, 11, 1712.
Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms 2023, 11, 1712.
Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms2023, 11, 1712.
Khenchouche, A.; Salem-Bekhit, M.M.; Mansour, A.A.; Alomary, M.N.; Wang, X.; Alzahrani, H.A.; Hosiny, I.M.A.; Taha, E.I.; Shazly, G.A.; Benguerba, Y.; Houali, K. Suppression of Nasopharyngeal and Gastric Tumor Growth in a Mouse Model by Antibodies to Epstein–Barr Virus LMP1 Protein. Microorganisms 2023, 11, 1712.
Abstract
Abstract: The study aimed to investigate the antitumor efficacy of anti-LMP1 antibodies in EBV-positive nasopharyngeal and stomach cell lines and xenograft models. The study also exam-ined the NF-κB expression and cell cycle activation of NPC serum exosome-associated LMP1. An-ti-LMP1 antibody treatment before or during cell implantation prevented tumor growth in nude mice. A small dose of antibodies resulted in complete tumor regression for at least three months af-ter the tumors had grown in size. The consumption of antigen-antibody complexes by tumor cells limited tumor growth. In vitro experiments showed that anti-LMP1 antibodies killed EBV-positive NPC- or GC-derived epithelial cell lines and EBV-positive human B cell lines but not EBV-negative cell lines. Treatment with anti-LMP1 reduced NF-κB expression in cells. The animal model experi-ments showed anti-LMP1 inhibited and prevented NPC- or GC-derived tumor growth. The results suggest that LMP1 antibody immunotherapy could cure nasopharyngeal cancer, EBV-positive gastric carcinoma, and EBV-associated lymphomas. However, further validation of these findings is required through human clinical trials.
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.